メニエール病に対するイソソルビド内服療法の長期投与による効果の臨床的評価:多施設二重盲検試験によるBetahistine Meyslateとの群間比較

概要

論文の詳細を見る
The clinical effect of isosorbide (TYS) for patients with Ménière's disease was first reported in 1981. Long-term treatment by TYS produced considerable symptomatic relief in many patients during the active stage of the disease. In the present study, the effect of TYS for patients with Ménière's disease was evaluated by a multi-centered double blind trial using betahistine meyslate (MR) as a reference drug over a period of 8 weeks. The indices that reflect global improvement and utility showed, by the Wilcoxon rank sum test (one-tailed), that the TYS was significantly (P<0.05) superior to the MR in the effectiveness of the control of Ménière's disease at 2 weeks, 4 weeks, 6 weeks and 8weeks after administration. There was no particular difference in the frequencies of side effects or abnormal clinical laboratory findings between groups treated with TYS and with MR. From the above results, it was concluded that TYS was an effective and useful drug for the treatment of Ménière's disease.
耳鼻と臨床会の論文